234 related articles for article (PubMed ID: 29356977)
1. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.
Armoiry X; Kan A; Melendez-Torres GJ; Court R; Sutcliffe P; Auguste P; Madan J; Counsell C; Clarke A
J Neurol; 2018 May; 265(5):999-1009. PubMed ID: 29356977
[TBL] [Abstract][Full Text] [Related]
2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.
Melendez-Torres GJ; Armoiry X; Court R; Patterson J; Kan A; Auguste P; Madan J; Counsell C; Ciccarelli O; Clarke A
BMC Neurol; 2018 Oct; 18(1):162. PubMed ID: 30285675
[TBL] [Abstract][Full Text] [Related]
5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
[TBL] [Abstract][Full Text] [Related]
7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
8. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
Comi G; Martinelli V; Rodegher M; Moiola L; Leocani L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Preziosa P; Ravnborg M; Rieckmann P; Rocca MA; Wynn D; Young C; Filippi M
Mult Scler; 2013 Jul; 19(8):1074-83. PubMed ID: 23234810
[TBL] [Abstract][Full Text] [Related]
9. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R;
Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
[TBL] [Abstract][Full Text] [Related]
12. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Signori A; Gallo F; Bovis F; Di Tullio N; Maietta I; Sormani MP
Mult Scler Relat Disord; 2016 Mar; 6():57-63. PubMed ID: 27063624
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
Katrych O; Simone TM; Azad S; Mousa SA
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):512-9. PubMed ID: 19811446
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
Spelman T; Frisell T; Piehl F; Hillert J
Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
Scott LJ
CNS Drugs; 2013 Nov; 27(11):971-88. PubMed ID: 24129744
[TBL] [Abstract][Full Text] [Related]
18. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
Kennedy P
J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S3-13. PubMed ID: 24217189
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
